Search Results

You are looking at 1 - 10 of 73 items for :

  • "zoledronic acid" x
Clear All
Full access

Kathleen Harnden and Kimberly Blackwell

growth beyond their potent antiosteoclast effects and to have systemic anticancer activity in operable breast cancer. In particular, nitrogen-containing bisphosphonates, such as zoledronic acid, have shown the most promising results in adjuvant breast

Full access

Richard L. Theriault

1997 ; 89 : 309 – 319 . 31 Roodman GD . Biology of osteoclast activation in cancer . J Clin Oncol 2001 ; 19 : 3562 – 3571 . 32 Mundy GR Yoneda T Hiraga T . Zoledronic acid and other bisphosphonates: Impact on the bone

Full access

Davide Mauri, Antonis Valachis, Nikolaos P. Polyzos, Lamprini Tsali, Dimitris Mavroudis, Vassilis Georgoulias and Giovanni Casazza

algorithm was used: [early OR adjuvant] AND [breast OR mammary] AND [tumour OR malign * OR carcinom * OR cancer] AND [biphosphonates OR bisphosphonates OR clodronate OR pamidronate OR zoledronic acid OR ibandronate]. The reference lists of all studies

Full access

Azeez Farooki

-term outcomes has been explored, 3 , 4 with provocative data still unfolding. A meta-analysis of more than 8,000 postmenopausal women with early-stage breast cancer who received zoledronic acid indicated a highly significant disease-free survival benefit. 3

Full access

Paul S. White, Michael Dennis, Eric A. Jones, Janice M. Weinberg and Shayna Sarosiek

Background Bone-modifying agents (BMAs) are an important component of supportive care for many patients with cancer. These agents include the intravenously administered bisphosphonates pamidronate and zoledronic acid, in addition to denosumab, a

Full access

Julie R. Gralow, J. Sybil Biermann, Azeez Farooki, Monica N. Fornier, Robert F. Gagel, Rashmi Kumar, Georgia Litsas, Rana McKay, Donald A. Podoloff, Sandy Srinivas and Catherine H. Van Poznak

;87:329–335. d Maillefert JF, Sibilia J, Michel F, et al. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 1999;161:1219–1222. e Gnant M, Jakesz R, Mlineritsch B, et al. Zoledronic acid

Full access

Siyang Leng, Yizhen Chen, Wei-Yann Tsai, Divaya Bhutani, Grace C. Hillyer, Emerson Lim, Melissa K. Accordino, Jason D. Wright, Dawn L. Hershman, Suzanne Lentzsch and Alfred I. Neugut

morbidity of bone disease in these patients, guidelines from NCCN, ASCO, International Myeloma Working Group, and European Myeloma Network all recommend use of the bisphosphonates zoledronic acid and pamidronate in patients receiving primary MM therapy. 2

Full access

Harold J. Burstein

guideline recommended using 1 of 3 treatments: denosumab, zoledronic acid, or pamidronate. The NCCN Guidelines for Breast Cancer 2 also recommend the exact same 3 drugs (to view the most recent version of these guidelines, visit the NCCN Web site at NCCN

Full access

Julie R. Gralow, J. Sybil Biermann, Azeez Farooki, Monica N. Fornier, Robert F. Gagel, Rashmi N. Kumar, Charles L. Shapiro, Andrew Shields, Matthew R. Smith, Sandy Srinivas and Catherine H. Van Poznak

action . Endocr Rev 1998 ; 19 : 80 – 100 . 46 Smith MR Eastham J Gleason DM . Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer . J Urol

Full access

. Mohler. Lastly, denosumab has been added to the NCCN Guidelines as an alternative to zoledronic acid for the prevention of skeletal-related events. “In men with castration-recurrent prostate cancer who have bone metastases, denosumab was shown